India's first dengue vaccine approved India's drug regulatory authority has approved the Kydenga vaccine against dengue for use. The dengue vaccine has been approved in India. The vaccine named Kydenga, developed by a Japanese company against the dengue virus, has been approved for use in India. Developed by Japanese pharmaceutical company Takeda Pharmaceuticals , this vaccine has been approved by India's drug regulatory authority Central Drug Standards and Organization (CDACO). The Kydenga vaccine is said to provide protection against all four types of dengue virus serotypes 1, 2, 3 and 4 . Like the COVID-19 vaccine , it requires two doses. The second dose should be given three months after the first dose. This vaccine, which can be given to people aged 4 to 60 years, can also be given to those who have not had dengue. This vaccine, which is currently being produced in India, currently costs between Rs 6,000 and Rs 12,000 per dose . The price is expected to come down in ...
Can measles be prevented by vaccination? Measles has existed in society for hundreds of years. The physician Abu Walker wrote about this disease for the first time in the tenth century. But the virus that causes this disease originated in the world 2600 years ago. Centuries ago, even doctors had trouble telling the difference between measles and smallpox. It was only in the seventeenth century that the British government listed these two diseases separately. Measles is a highly contagious disease. One infected person can infect up to 18 people. Before the introduction of the measles vaccine, the disease was widespread around the world, and countless children died because of it. It is estimated that more than 2 million people worldwide died from measles before measles vaccines were available. If a person who has not been vaccinated against measles gets infected with measles, 10 to 30 percent of those infected may die due to complications. In 1874, a third of the infected died in a ...